Market Research Industry Reports

Moberg Pharma AB (MOB) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged nails, Fast relief of pain and itch, Waterproof liquid bandage, minor skin irritations, diaper rash, skin irritation and rash and dry feet and cracked heels in one step. The company works in collaboration to develop Oral mucositis for the treatment of pain in the oral cavity. It offers licencing in and licencing out services. The company markets its products in Europe, South America, Africa, the Middle East and others. Moberg Pharma is headquartered in Stockholm, Sweden.

Moberg Pharma AB (MOB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Moberg Pharma Acquires DermoPlast from Prestige 13
Moberg Pharma Acquires PediaCare Brands from Strides Pharma for USD5.6 Million 15
Moberg Pharma Acquires Three US OTC Brands from Prestige Brands for USD40 Million 16
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 18
Moberg Pharma Acquires Bupivacaine From Oracain 19
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 20
Partnerships 21
Moberg Pharma Enters into Agreement with Colep 21
Moberg Extends Distribution Agreement with Menarini for Emtrix 22
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 23
Moberg Pharma Extends Distribution Agreement With Menarini 24
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 25
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 26
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 27
Moberg Derma Enters Into Co-Marketing Agreement With Ana Darou For Emtrix 28
Licensing Agreements 29
Cadila Pharma Enters into Licensing Agreement with Moberg Pharma 29
Equity Offering 30
Moberg Pharma to Raise USD16 Million in Private Placement of Shares 30
Moberg Pharma Raises USD8.6 Million in Private Placement of Shares 31
Moberg Pharma Completes Rights Offering Of Shares For US$5 Million 33
Debt Offering 34
Moberg Pharma Raises USD32.8 million in Public Offering of Bonds 34
Asset Transactions 35
Randob Labs Acquires Balmex from Moberg Pharma for USD4.2 Million 35
Strides Shasun Acquires Jointflex, Fergon and Vanquish Brands from Moberg Pharma for USD10 Million 36
Acquisition 37
Altaris Capital Sells Minority Stake in Moberg Pharma 37
Moberg Derma Completes Acquisition Of Alterna From Altaris Capital Partners For US$25 Million 38
Moberg Pharma AB - Key Competitors 40
Moberg Pharma AB - Key Employees 41
Moberg Pharma AB - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 07, 2018: Moberg Pharma interim report January - June 2018 43
May 08, 2018: Moberg Pharma Interim report January - March 2018 45
Feb 13, 2018: Moberg Pharma Year-end Report 2017 47
Nov 13, 2017: Moberg Pharma interim report January - September 2017 49
Aug 08, 2017: Moberg Pharma: interim report January- June 2017 51
May 09, 2017: Moberg Pharma interim report January - March 2017 53
Feb 14, 2017: Moberg Pharma Year-end report 2016 54
Corporate Communications 56
Aug 13, 2018: Moberg Pharma appoints new chief medical officer 56
Apr 19, 2018: Moberg Pharma Announces Resignation Of Kjell Rensfeldt As VP Research and Development 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List Of Tables


Moberg Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Moberg Pharma Acquires DermoPlast from Prestige 13
Moberg Pharma Acquires PediaCare Brands from Strides Pharma for USD5.6 Million 15
Moberg Pharma Acquires Three US OTC Brands from Prestige Brands for USD40 Million 16
Moberg Pharma Acquires Balmex from Chattem for USD3.9 Million 18
Moberg Pharma Acquires Bupivacaine From Oracain 19
Moberg Pharma Completes Acquisition Of Over-The-Counter Brands From Bayer HealthCare For US$4.8 Million 20
Moberg Pharma Enters into Agreement with Colep 21
Moberg Extends Distribution Agreement with Menarini for Emtrix 22
Moberg Pharma Extends Distribution Agreement with Berlin-Chemie for Emtrix 23
Moberg Pharma Extends Distribution Agreement With Menarini 24
Moberg Extends Distribution Agreement With Menarini For Kerasal Nail 25
Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 26
Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 27
Moberg Derma Enters Into Co-Marketing Agreement With Ana Darou For Emtrix 28
Cadila Pharma Enters into Licensing Agreement with Moberg Pharma 29
Moberg Pharma to Raise USD16 Million in Private Placement of Shares 30
Moberg Pharma Raises USD8.6 Million in Private Placement of Shares 31
Moberg Pharma Completes Rights Offering Of Shares For US$5 Million 33
Moberg Pharma Raises USD32.8 million in Public Offering of Bonds 34
Randob Labs Acquires Balmex from Moberg Pharma for USD4.2 Million 35
Strides Shasun Acquires Jointflex, Fergon and Vanquish Brands from Moberg Pharma for USD10 Million 36
Altaris Capital Sells Minority Stake in Moberg Pharma 37
Moberg Derma Completes Acquisition Of Alterna From Altaris Capital Partners For US$25 Million 38
Moberg Pharma AB, Key Competitors 40
Moberg Pharma AB, Key Employees 41
Moberg Pharma AB, Subsidiaries 42

List Of Figures


Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Moberg Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Moberg Pharma AB, Medical Devices Deals, 2012 to YTD 2018 10

Moberg Pharma AB (MOB) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma

USD 250View Report

Moberg Pharma AB Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Moberg Pharma AB Company Profile is a detailed strategic and analytical report on Moberg Pharma AB. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Asarina Pharma AB - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Asarina Pharma AB (Asarina Pharma), formerly Umecrine Mood AB, a subsidiary of Umecrine AB, is a sepranolone product developer. The company offers discovery, development and commercialization of novel treatments for

USD 250View Report

A1M Pharma AB - Pharmaceuticals and Healthcare - Deals and Alliances Profile

A1M Pharma AB (A1M Pharma) is a developer of a medical application for the diagnosis and treatment of pre-eclampsia and acute renal damage. The company develops and commercializes drug candidate

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Sep 2018
No. of Pages :58
Country :Sweden
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube